PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1555743
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1555743
Submucosal Lifting Agent Market size was valued at USD 115.90 Million in 2023, expanding at a CAGR of 7.20% from 2024 to 2032.
A submucosal lifting agent is a medical substance used to elevate the mucosal layer during endoscopic procedures. Its primary application is in facilitating the removal of polyps, adenomas, and early-stage cancers by creating a cushion between the mucosa and underlying tissues. This lifting action allows for clearer visibility and easier manipulation of lesions, improving the precision and effectiveness of procedures like endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). The agents are valued for their safety, efficacy, and ability to minimize complications during such interventions.
Submucosal Lifting Agent Market- Market Dynamics
The rising prevalence of gastrointestinal conditions, such as polyps, adenomas, and early-stage cancers
The increasing incidence of gastrointestinal disorders is a major factor driving the submucosal lifting agent market. For example, colorectal cancer, which often involves polyps and adenomas as precursors, is one of the most common cancers globally, with over 1.9 million new cases reported in 2020 alone. The prevalence of adenomatous polyps, which can progress to cancer if untreated, is significant, with studies indicating that up to 30% of adults over 50 may have these polyps. The rise in diagnoses has led to a greater need for precise endoscopic techniques, such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), which rely on effective submucosal lifting agents. These agents help in creating a cushion between the mucosa and underlying tissues, enhancing the ability to remove and treat these lesions safely and effectively, thereby supporting the growing market for these products.
Submucosal Lifting Agent Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2024-2032)
Based on Ingredient segmentation, Sodium hyaluronate was predicted to show maximum market share in the year 2023
Based on Application segmentation Polyps was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Submucosal Lifting Agent Market is segmented on the basis of Ingredient, Application, End USer, and Region.
The market is divided into six categories based on Ingredient: Sodium hyaluronate is often regarded as the most prominent ingredient in its class because of its exceptional ability to provide a stable submucosal lift. Its effectiveness is well-documented in clinical practice, where it is widely used due to its superior performance in mucosal lifting. Also, sodium hyaluronate is highly valued for its excellent biocompatibility, ensuring that it integrates seamlessly with the body's tissues, and its strong safety profile, which minimizes the risk of adverse reactions. This combination of efficacy, compatibility, and safety makes it a preferred choice in various medical and aesthetic applications.
The market is divided into five categories based on Application: Polyps often lead as the primary segment. This is because submucosal lifting is commonly employed in the removal and treatment of polyps, particularly in procedures like endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). These techniques rely on the effective lifting of the mucosal layer to facilitate the precise removal of polyps and other lesions, making polyps a significant focus in this area.
Submucosal Lifting Agent Market- Geographical Insights
The North American market for submucosal lifting agents is characterized by strong demand for minimally invasive procedures and rapid technological advancements. The region benefits from a well-established healthcare infrastructure and a focus on enhancing endoscopic techniques. Regulatory approvals and clinical efficacy are critical factors driving market growth. The regional landscape is shaped by continuous innovation and research, with an emphasis on improving product performance and safety.
Key players in the submucosal lifting agent market include Olympus, Medtronic, and EndoClot Plus. These companies lead the industry with advanced products designed to enhance endoscopic procedures by lifting the mucosal layer for better visualization and manipulation. The market also features contributions from smaller, innovative firms that are developing new formulations and delivery systems. Growth in this sector is supported by technological advancements in endoscopy, increasing demand for minimally invasive procedures, and ongoing research to enhance the effectiveness and safety of these agents.
In April 2023, Olympus announced the launch of EndoClot(R) Adhesive (ECA), EndoClot(R) Polysaccharide Hemostatic Spray (PHS), and EndoClot(R) Submucosal Injection Solution (SIS) across Europe, the Middle East, and Africa (EMEA).
In Sept 2022, Olympus Announces the U.S. Distribution of EndoClot Polysaccharide Hemostatic Spray and EndoClot Submucosal Injection Agent.